Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $271 to $275.
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $271 to $275.